Terms: = Endocrine gland cancer AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027
9 results:
1. Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
de la Rosa CN; Krell J; Day E; Clarke A; Reddi M; Webber L; Fiorentino F
Trials; 2022 Jan; 23(1):13. PubMed ID: 34986897
[TBL] [Abstract] [Full Text] [Related]
2. "Pancreatic Mucoepidermoid Carcinoma" Is not a Pancreatic Counterpart of crtc1/3-MAML2 Fusion Gene-related Mucoepidermoid Carcinoma of the Salivary gland, and May More Appropriately be Termed Pancreatic Adenosquamous Carcinoma With Mucoepidermoid Carcinoma-like Features.
Saeki K; Ohishi Y; Matsuda R; Mochidome N; Miyasaka Y; Yamamoto H; Koga Y; Maehara Y; Nakamura M; Oda Y
Am J Surg Pathol; 2018 Nov; 42(11):1419-1428. PubMed ID: 30138216
[TBL] [Abstract] [Full Text] [Related]
3. Vistusertib (dual m-torc1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Basu B; Krebs MG; Sundar R; Wilson RH; Spicer J; Jones R; Brada M; Talbot DC; Steele N; Ingles Garces AH; Brugger W; Harrington EA; Evans J; Hall E; Tovey H; de Oliveira FM; Carreira S; Swales K; Ruddle R; Raynaud FI; Purchase B; Dawes JC; Parmar M; Turner AJ; Tunariu N; Banerjee S; de Bono JS; Banerji U
Ann Oncol; 2018 Sep; 29(9):1918-1925. PubMed ID: 30016392
[TBL] [Abstract] [Full Text] [Related]
4. Case of parotid mucoepidermoid carcinoma: Expanding the spectrum of von Hippel-Lindau-related neoplasms.
Berger MH; Kerr DA; Rangel Filho AE; Sargi ZB
Head Neck; 2017 Mar; 39(3):E51-E54. PubMed ID: 28006088
[TBL] [Abstract] [Full Text] [Related]
5. Enhanced mitochondrial glutamine anaplerosis suppresses pancreatic cancer growth through autophagy inhibition.
Jeong SM; Hwang S; Park K; Yang S; Seong RH
Sci Rep; 2016 Aug; 6():30767. PubMed ID: 27477484
[TBL] [Abstract] [Full Text] [Related]
6. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
[TBL] [Abstract] [Full Text] [Related]
7. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
Clin Cancer Res; 2011 Oct; 17(20):6482-9. PubMed ID: 21831957
[TBL] [Abstract] [Full Text] [Related]
8. crtc1/MAML2 fusion transcript in Warthin's tumor and mucoepidermoid carcinoma: evidence for a common genetic association.
Bell D; Luna MA; Weber RS; Kaye FJ; El-Naggar AK
Genes Chromosomes Cancer; 2008 Apr; 47(4):309-14. PubMed ID: 18181164
[TBL] [Abstract] [Full Text] [Related]
9. crtc1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior.
Tirado Y; Williams MD; Hanna EY; Kaye FJ; Batsakis JG; El-Naggar AK
Genes Chromosomes Cancer; 2007 Jul; 46(7):708-15. PubMed ID: 17437281
[TBL] [Abstract] [Full Text] [Related]
